ITUS - ITUS Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.98
-0.05 (-1.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.03
Open4.110
Bid3.52 x 300
Ask4.85 x 200
Day's Range3.94 - 4.11
52 Week Range0.60 - 6.43
Volume102,636
Avg. Volume669,291
Market Cap66.192M
Beta1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.12
Trade prices are not sourced from all markets
  • PR Newswire22 days ago

    ITUS Presentation to Special Meeting of Stockholders

    SAN JOSE, Calif., April 2, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar, at its Special Meeting of Stockholders on March 29, 2018 has been placed on the Company's website.  It can be viewed at http://ir.ituscorp.com/corporate-presentation.

  • ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study
    PR Newswire28 days ago

    ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

    SAN JOSE, Calif., March, 27, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that it has completed a prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.

  • ITUS Announces Issuance of Second Key Cancer Detection Technology Patent
    PR Newswire29 days ago

    ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

    SAN JOSE, Calif. , March 26, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent ...

  • Where ITUS Corporation (NASDAQ:ITUS) Stands In Earnings Growth Against Its Industry
    Simply Wall St.last month

    Where ITUS Corporation (NASDAQ:ITUS) Stands In Earnings Growth Against Its Industry

    When ITUS Corporation (NASDAQ:ITUS) released its most recent earnings update (31 January 2018), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting
    PR Newswirelast month

    ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting

    SAN JOSE, Calif. , March 16, 2018 /PRNewswire/ --   ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early cancer detection study at the annual meeting ...

  • ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting
    PR Newswirelast month

    ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

    SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be made at the annual meeting of the American Association of Cancer Research (AACR) in Chicago, Illinois.  The meeting will be held April 14-18, 2018 and will be attended by world leading experts across the field of cancer research.  All abstracts will be viewable by registered attendees beginning March 14, 2018.  To receive a copy of the presentation, please email your request to AACR-2018@ITUScorp.com starting April 19, 2018 and include your name, title, and contact information. The presentation will focus on ITUS' proprietary Cchek™ platform featuring new data and insights into this early cancer detection technology.  Cchek™ combines the immunophenotyping of white blood cells using flow cytometry with a proprietary neural network, a type of artificial intelligence (AI), to detect the presence of solid tumors from a blood sample.  Identifying and measuring circulating myeloid-derived suppressor cells (MDSCs), a group of immunosuppressive white blood cells, is the foundation of this technology.

  • ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
    PR Newswire2 months ago

    ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

    SAN JOSE, Calif. , March 9, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that John Roop , Senior Vice President of Engineering is scheduled to present on Friday March 16, 2018 , ...

  • ITUS Corporation Forms Alliance with Serametrix Corporation
    PR Newswire2 months ago

    ITUS Corporation Forms Alliance with Serametrix Corporation

    SAN JOSE, Calif., March 5, 2018 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS's proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix's substantial expertise in immune monitoring assays.  Serametrix flow cytometry and related data analysis services are already widely used in immunotherapy drug trials.

  • ITUS will Present Artificial Intelligence Powered Early Cancer Detection Technology at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations
    PR Newswire2 months ago

    ITUS will Present Artificial Intelligence Powered Early Cancer Detection Technology at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations

    SAN JOSE, Calif., Feb. 7, 2018 /PRNewswire/ -- ITUS Corporation (ITUS), today announced that its presentation titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," has been accepted for presentation at the Keystone Symposia Conference - Cancer Immunotherapy: Combinations in Montreal, Quebec, Canada.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology. The presentation will focus on ITUS' proprietary Cchek™ platform which utilizes immuno-profiling via Flow Cytometry and Artificial Intelligence to enable the detection of solid tumors from a blood sample.

  • ACCESSWIRE3 months ago

    Blog Exposure - ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

    Stock Monitor: Alliance Data Systems Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 31, 2018 / Active-Investors.com has just released a free research report on ITUS Corp. (NASDAQ: ITUS ).If ...

  • Business Wire3 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of ITUS Corporation

    Levi & Korsinsky announces it has commenced an investigation of ITUS Corporation concerning possible breaches of fiduciary duty. To obtain additional information

  • ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium
    PR Newswire3 months ago

    ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

    Statistics clearly show that when cancer is detected early (Stage I or II), the chances of long term survival are often greater than 95%, or even 100% in some cases. However, if the cancer is detected late (Stage III or IV), the probability of long term survival declines to levels as low as 10%.  Understandably, there has been tremendous interest from the scientific and investment community in the development of techniques for early cancer detection.  ITUS, one of the few publicly traded companies operating in this arena, utilizes a proprietary technique to monitor changes in a patient's immune system driven by the presence of a tumor. Studies over the past decade have demonstrated that there is a dynamic interaction between a patient's immune system and the existence of a tumor.

  • Is ITUS Corporation (NASDAQ:ITUS) Thriving Or Barely Surviving In The Tech Sector?
    Simply Wall St.3 months ago

    Is ITUS Corporation (NASDAQ:ITUS) Thriving Or Barely Surviving In The Tech Sector?

    ITUS Corporation (NASDAQ:ITUS), is a $100.49M small-cap, which operates in the tech hardware industry based in United States. As various enterprises look to technology to enable their own transformations, theRead More...

  • ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26
    PR Newswire3 months ago

    ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26

    The presentation abstract titled, "The coupling of MDSCs with a computational analytic method to detect solid tumors," will be released on January 22nd, however the underlying data will be kept confidential until the presentation on January 26th.  Myeloid-derived suppressor cells, or MDSCs, are a key group of white blood cells that form the foundation for ITUS' liquid biopsy technology.

  • Who Are The Major Shareholders Of ITUS Corporation (NASDAQ:ITUS)?
    Simply Wall St.3 months ago

    Who Are The Major Shareholders Of ITUS Corporation (NASDAQ:ITUS)?

    I am going to take a deep dive into ITUS Corporation’s (NASDAQ:ITUS) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structure isRead More...

  • Is ITUS Corporation (NASDAQ:ITUS) Overpaying Its CEO?
    Simply Wall St.4 months ago

    Is ITUS Corporation (NASDAQ:ITUS) Overpaying Its CEO?

    Amit Kumar has been at the helm as CEO of ITUS Corporation (NASDAQ:ITUS), which has grown to a market capitalization of USD$44.54M. Recognizing whether CEO incentives are aligned with shareholdersRead More...

  • ITUS Corporation Terminates At-The-Market Offering
    PR Newswire4 months ago

    ITUS Corporation Terminates At-The-Market Offering

    SAN JOSE, Calif. , Dec. 12, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), announced today that it has terminated its at-the-market equity program ("ATM Offering") with B. Riley FBR, Inc.  ...

  • ITUS Will Present Data on Early Cancer Detection Technology at ASCO-SITC Symposium
    PR Newswire5 months ago

    ITUS Will Present Data on Early Cancer Detection Technology at ASCO-SITC Symposium

    SAN JOSE, Calif. , Dec. 6, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that its abstract titled, " The coupling of MDSCs with a computational analytic method to detect solid ...

  • ACCESSWIRE5 months ago

    SeeThruEquity Initiates Coverage on ITUS Corporation (NASDAQ: ITUS) with a Price Target of $5.00

    NEW YORK, NY / ACCESSWIRE / December 5, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...

  • ITUS Corporation (ITUS): Should The Recent EPS Drop Worry You?
    Simply Wall St.5 months ago

    ITUS Corporation (ITUS): Should The Recent EPS Drop Worry You?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • ITUS Receives Notice of Allowance for Second Key Cancer Technology Patent
    PR Newswire5 months ago

    ITUS Receives Notice of Allowance for Second Key Cancer Technology Patent

    SAN JOSE, Calif. , Nov. 28, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent ...

  • American City Business Journals5 months ago

    How Moffitt could play a role in finding a treatment for ovarian cancer

    A California biotechnology company has signed an agreement with Moffitt Cancer Center in Tampa to do the research and development work for a potential immunotherapy to treat ovarian cancer. ITUS Corp. (ITUS), based in San Jose, California, will pay Moffitt about $1.2 million over two years, as part of a cooperative research and development agreement, Amit Kumar, president and CEO of ITUS, said in a conference call Tuesday. Leading the work will be Dr. Jose Conejo Garcia, a Moffitt researcher and principal investigator.

  • ITUS Conference Call Recording Available on Company Website
    PR Newswire5 months ago

    ITUS Conference Call Recording Available on Company Website

    SAN JOSE, Calif. , Nov. 22, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has made available at www.ituscorp.com , the recording of its November 21, 2017 conference call.  ...

  • ITUS Will Hold Conference Call to Discuss its CAR-T Cancer Therapeutics Program
    PR Newswire5 months ago

    ITUS Will Hold Conference Call to Discuss its CAR-T Cancer Therapeutics Program

    SAN JOSE, Calif. , Nov. 21, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) reminds interested parties that it will be holding a conference call today at 2 p.m. Pacific/ 5 p.m. Eastern to discuss ...

  • ITUS Enters CAR-T Research Alliance with Moffitt Cancer Center
    PR Newswire5 months ago

    ITUS Enters CAR-T Research Alliance with Moffitt Cancer Center

    SAN JOSE, Calif., Nov. 20, 2017 /PRNewswire/ -- ITUS Corporation (ITUS) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with Moffitt Cancer Center, to advance toward human clinical testing, a Chimeric Antigen Receptor T-Cell (CAR-T) technology aimed initially at Ovarian Cancer, and eventually additional solid tumors. This technology was developed at The Wistar Institute and licensed by ITUS through its majority-owned subsidiary corporation, Certainty Therapeutics, Inc.